Dr Anthony Noble has experience and background in the natural products and biotechnology industries. He was involved in establishing and expanding business operations in Korea, Canada and the USA, and close cooperation with partners in Indonesia.
Dr Noble became the chief executive of Fiji Kava in May 2021. Prior to that, he was the managing director and chief executive of Australian Biotherapeutics where he contracted and commissioned a single-use bioreactor facility in Queensland which was built after securing government and investor funding, and a distribution contract in the USA. Dr Noble also has domestic and international experience from his time at SFI Group, including as managing director of SFI Research and global head of innovation at SFI Group. He was SFI Group's head of North Asia, business to business and general manager of the group's Chinese joint venture.
Prior to the SFI Group, Dr Noble's experience in the biotechnology industry included roles as principal scientist and marketing manager of Cryosite, Australian Cord Blood Service, where he gained new business licenses and grew the division via healthcare practitioners and consumer marketing programs. He had worked in the UK as lead inspector and regulation director for the Human Tissue Authority, the implementation of regulations for Advanced Therapy Medicinal Products including cell and gene therapies, and represented the Authority on working groups in the European Medicines Agency and the MHRA.
